Comparison of the effects of Mylabris and Acanthopanax senticosus on promising cancer marker polyamines in plasma of a Hepatoma‐22 mouse model using HPLC‐ESI‐MS. (5th July 2012)

• Record Type: Journal Article
• Authors: Wang, Qian; Wang, Yixiang; Liu, Ran; Yan, Xu; Li, Yujiao; Fu, Hui; Bi, Kaishun; Li, Qing
• Is Part Of: Biomedical chromatography. Volume 27:Number 2(2013:Feb.)
• Page Start: 208
• Page End: 215
• Publication Date: 2012-07-05
• Subjects: Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.2777
• Languages: English
• ISSNs: 0269-3879

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <p>A simple and sensitive method for the simultaneous determination of plasma concentrations of five polyamines in normal and Hepatoma‐22 mice, and mice treated with Mylabris and <italic>Acanthopanax senticosus</italic> was developed by HPLC‐ESI‐MS. Male Kunming mice were divided into nine groups, a control group (inoculation without treatment), a positive group (Cyclophosphamide), treatment groups [Mylabris (4, 8, 16 mg/kg), <italic>Acanthopanax senticosus</italic> (6, 12, 24 g/kg)] and a normal group (without inoculation). Twenty‐four hours after the last administration, plasma samples were collected. The derived polyamines were separated on a C₁₈ column by a gradient elution using methanol–water with excellent linearity within the range from 2.5 to 1000 ng/mL. Polyamines were confirmed as useful biochemical markers of hepatoma. The differences in anti‐cancer therapeutic efficacy between Mylabris and <italic>Acanthopanax senticosus</italic> might contribute to the variability of polyamine levels <italic>in vivo</italic>. This HPLC‐ESI‐MS method was successfully applied to investigate the relationship between polyamines and cancer in mice and might be a useful method to test the activity of potential anti‐tumor drugs. Copyright © 2012 John Wiley &amp; Sons, Ltd.</p> </abstract>